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Background: Chlamydia Trachomatis is one of the most common pathogens
transmitted through the genital tract in humans that leads to urogenital infection.
Objective: Given the high prevalence of chlamydia infection and its adverse effects on
the health of women and men, the present meta-analysis was conducted to determine
the rate of treatment failure with azithromycin.
Materials and Methods: Databases including MEDLINE, ISI - Web of Science, PubMed,
EMBASE, Scopus, ProQuest, and Science Direct were searched for articles published
between 1991 and 2018. The quality of the selected articles was assessed using the
Cochrane risk of bias assessment tool. Heterogeneity was determined using the I2 and
Cochrane Q-Test. Subgroup analysis and meta-regression were used to compare the
prevalence rates on different levels of the variables.
Results: A total of 21 articles that met the inclusion criteria were ultimately assessed. The
pooled estimate of azithromycin failure rate was 11.23% (CI 95%: 8.23%-14.24%). Also,
the azithromycin failure rate was 15.87% (CI 95%: 10.20%-21.54%) for the treatment of
urethritis, 7.41% (CI 95%: 0.60%-14.22%) for cervicitis, and 7.14% (CI 95%: 10.90%-3.39%)
for genital chlamydia. The pooled estimate of failure rate difference was 2.37% (CI
95%: 0.68%-4.06%), which shows that azithromycin has a higher failure rate in the
treatment of chlamydia compared to doxycycline and other examined medications.
The meta-regression results showed that the patient’s age contributes significantly to
the heterogeneity for azithromycin treatment failure rate (β = 0.826; p = 0.017).
Conclusion: Azithromycin has a higher failure rate than doxycycline and other studied
medications in treating urogenital chlamydia infections.
Key words: Azithromycin, Chlamydia trachomatis, Urogenital, Treatment failure,
Meta-analysis.
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1. Introduction
Chlamydia Trachomatis is an intracellular
gram-negative bacterium and one of the most
common pathogens transmitted through the genital
tract in humans and causing urogenital infection.
Chlamydia is one of the most common Sexually
Transmitted Diseases (STDs) in the world, which
has a higher prevalence among adolescents
and women (1). According to the latest World
Health Organization (WHO) reports, the reported
prevalence of chlamydia has steadily increased
over the last two decades, and 92 million new
cases of chlamydia trachomatis infection occurred
in 2009, reaching 101, 131, and 153 million in
2011, 2012, and 2015, respectively (2, 3). The
risk factors for chlamydial infection include age
15–24, several sexual partners, unprotected sex,
and previous history of STDs. Being single and a
poor socioeconomic status and education level is
also associated with the incidence of this disease
(4, 5).
The results from previous studies suggest that
chlamydia trachomatis infection entails the risk
of cervicitis, urinary tract infections, prostatitis,
epididymitis, peritonitis, lower respiratory tract
diseases, chronic fatigue syndrome, and reactive
arthritis. It also doubles the risk of ectopic
pregnancy (6, 7) and increases the risk of
developing the inflammatory pelvic disease in
recurring chlamydial infections or treatment failures
by 4–6 times (8). Chlamydia infection also increases
the likelihood of Human Immunodeficiency Virus
(HIV) comorbidity. Infertility is one of the
common complications of untreated chlamydial
cervicitis, whose likelihood increases with the
frequency of recurrence or treatment failure
(9, 10). The proposed treatment of Chlamydial
cervicitis is a single dose of oral azithromycin
or oral doxycycline 100 mg twice daily for
seven days. Alternative therapies include oral
tetracycline 500 mg four times daily for seven
days, oral erythromycin 500 mg four times daily
for seven days, and oral ofloxacin 200 mg
twice daily for seven days. According to the
latest WHO guidelines, the evidence derived
from comparing different chlamydial infection
treatment regimens is poor to moderate, and
further controlled, randomized, trials comparing
these treatments and recommended doses are
necessary (11).
Azithromycin treatment failure was first reported
in Australia and subsequently documented in
several continents. The common causes of
treatment failure include bacterial resistance
to azithromycin, improper absorption of
azithromycin by the upper vagina, and the
ineffective antibiotic coverage of this routine
treatment on certain common pathogenic
bacteria associated with chlamydia infection.
Recent studies have shown a prevalence of
41.4% (range: 17.7% to 56.6%) for mutations
related to the resistance of Chlamydiatrachomatis
strains against azithromycin (5, 12–14). Since the
failure to choose properly covering antibiotics
and frequent treatment failures for chlamydial
cervicitis cause incurable infections that entail
a risk of inflammatory pelvic disease, urinary
tract infections, peritonitis, ectopic pregnancy,
premature rupture of the amniotic sac and
infertility, further clinical studies are required
to determine the right treatment program and
medication dosage for an effective clinical
treatment (15–19).
Studies show contradictory information
regarding treatment failure with azithromycin
for chlamydial infection compared to other
treatment strategies. Since systematic review
studies summarize the reported results and
provide evidence in the best way and with great
clarity (20), the present meta-analysis study was
conducted to determine the rate of treatment
failure with azithromycin in patients with urogenital
chlamydial infection.
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2. Materials and Methods
2.1. Search strategy
The preferred reporting items for systematic
reviews and meta-analyses (PRISMA) guidelines
were followed to report the findings of
this study. Studies published before August
2018 were identified without any language
restrictions through an electronic search of
databases including MEDLINE, ISI - Web
of Science, PubMed, EMBASE, Scopus,
ProQuest, and Science Direct. A combination
of keywords including “Azithromycin” or
“AZT” or “Single-dose Azithromycin” and
“Chlamydia trachomatis” or “Chlamydia” or
“Genital chlamydia infection” or “Urethritis” or
“Cervicitis” or “Endocervicitis” or “Cervicovaginitis”
or “Urogenital” or “Rectal chlamydia”, and
“Treatment failure” or “failure” were used to
collect data.
2.2. Eligibility criteria
Trials comparing azithromycin with doxycycline
or other medications for the treatment of
Chlamydiatrachomatis in women (cervicitis,
urethritis, and rectal infection) or men (urethritis
and rectal infection) were assessed. The inclusion
criteria were: (1) Being a randomized clinical trial or
a clinical trial; (2) Comparing treatment regimens
of oral azithromycin (single- or multiple-dose
regimens) with oral doxycycline (twice daily
100 mg for seven days) or other regimens;
(3) Being a man or woman over the age of
12; (4) Assessment of microbial or clinical
recovery during a follow-up period of 1–9 wk;
and (5) Reporting treatment failure during the
trial.
The articles that had published only their
abstract, the in vitro or in vivo studies, anything other
than Randomized Controlled Trials (RCTs) or clinical
trials, and articles that did not provide the numerical
outcome data were eliminated.
2.3. Study selection
The eligibility of the articles was assessed
independently by two authors, and any
disagreements were resolved by consensus.
A total of 604 irrelevant or duplicate articles
were eliminated in this stage. The assessment of
the articles and abstracts led to the exclusion of
another 497 articles. In assessing the full texts, 22
articles out of the remaining 43 did not meet the
eligibility criteria and were excluded. A total of 21
eligible articles were ultimately assessed (Table I
and Figure 1).
2.4. Quality assessment
The risk of bias was independently assessed
by these authors using the Cochrane risk of
bias assessment tool. The risks identified were
compared, and disagreements were resolved by
consensus. The risk of bias assessment also
entailed an evaluation of the randomization method,
allocation concealment, blinding of participants,
researchers and assessors, incomplete outcome
data, and selective outcome reporting (Table II)
(21).
2.5. Data extraction
The first author’s name, article publication
year and country, study design, participants’
number and age, main complaint, diagnostic
method, intervention group, the control group,
follow-up period, and treatment failure were
extracted and included in the analysis. Microbial
recovery was defined as Chlamydia Trachomatis
negativity in the biological assay (culture,
enzyme immunoassay (EIA), or DNA amplification
tests).
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Table II. Risk of bias summary: Authors’ judgments about each risk of bias item for each included study






















Green = Low risk of bias; Red = High risk of bias; Yellow = Unknown bias
2.6. Statistical analyses
All the analyses were performed in Stata-14.0
(College Station, Texas) in two parts. First, the
percentage of treatment failure with azithromycin
in each study was extracted, and the standard




and the pooled failure rate of azithromycin was then
found by inverse variance weighting. In the second
part, the difference of failure rates in each study was
calculated (Difference of failure rate = Failure rate in
the intervention group - Failure rate in the control





+ pcontrol (1−pcontrol )ncontrol .
Then, the pooled difference of failure rates
was obtained by inverse variance weighting. In
both parts, heterogeneity was determined by
Cochran’s Q-Test of heterogeneity and quantified
using the I2 index. Based on Higgins’ classification,
an I2 > 0.7 was regarded as indicative of
high heterogeneity. The pooled value was
estimated using the fixed-effect model, and when
heterogeneity exceeded 0.7, the random-effect
model was used. In both parts, the meta-regression
method was used to assess the effect of age,
publication year, type of study, sample size, type
of disease, and follow-up as factors affecting
heterogeneity among the studies. Also, Begg’s
test was used to investigate the publication bias;
α = 0.05 was considered as the level of statistical
significance in all the analyses.
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Records after the removal of 
duplicates (n = 107)
Full text articles assessed for
eligibility (n = 43) Full-text articles excluded (n = 22):
Reasons:
Review article (n = 2)
Not clinical trial (n = 7)
Protocol study (n = 1)
In vitro (n = 6)
Did not include outcomes of     
interest (n = 3)
Incomplete data (n = 3)Articles included in the review 
(n = 21)
Records identified through database 
searching (n = 604)





Figure 1. Flowchart showing the selection of studies.
3. Results
The discussed stages led to the selection of
21 studies. Table I presents a full description of
the selected studies. A brief description of these
studies follows. The studies were all double-blind
or single-blind and had open-label designs. The
sample size of the selected studies varied from 26
to 1,787. A total of 6,284 people thus participated
in this review study through the selected studies.
The participants were of different ages and from
different countries. The selected studies were RCTs
(n = 19) or CTs (n = 2), and their follow-up periods
varied from 1 to 9 wk.
The complaint of the patients with chlamydia
included cervicitis (4), urethritis (8), and urogenital
chlamydia (9). Chlamydia was diagnosed based
on an EIA, cultures, the Nucleic-Acid Amplification
Test (NAAT), Gram-stain, the Direct Fluorescence
Assay (DFA), and clinical examinations, and the main
outcome in all the studies was the assessment
of the failure rate with azithromycin compared
to other treatment strategies (i.e., Doxycycline,
Rifalazil, Lymecycline, and Amoxicillin).
Since the percentage of treatment failure was
reported as zero for the studies conducted by
Geisler (22), Jang (23), Rustomjee (24), Skerke (25),
Thorpe (26), Brihmer (27), and Lauharanta (28), 0.05
units were added to all of them in the meta-analysis
to enable the inclusion of their reported results
in the pooled analysis. Also, because of a high
heterogeneity (I2 value for pooled estimate of failure
rate was 94.7% (p < 0.001), random effects method
was used.
The results of assessing the 21 studies showed
that the pooled estimate of azithromycin failure rate
was 11.23% (95% CI: 8.23%-14.24%; Figure 2), and
the pooled estimate of the failure rate difference
was 2.37% (95% CI: 0.68%-4.06%; Figure 3).
In the present study, the azithromycin failure rate
in the patients with chlamydial urethritis was 15.87%
(CI 95%: 10.20%-21.54%; Figure 4), and the failure
rate difference was 3.67% (CI 95%: -0.44%-7.77%;
Figure 3). The azithromycin failure rate in the
patients with chlamydial cervicitis was 7.41%
(CI 95%: 0.60%-14.22%; Figure 4), and the failure
rate difference was 0.86% (CI 95%: -1.14%-2.87%;
Figure 3).
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In the patients with genital chlamydia, the azi-
thromycin failure rate was 7.14% (CI 95%:
10.90%-3.39%; Figure 4), and the failure rate
difference was 1.90% (CI 95%: -0.04%-3.83%;
Figure 3). Tables III and IV show meta-regression
results in order to identify the variables
affecting the heterogeneity. According to this,
the meta-regression results revealed that the
patient’s age had a significant effect on the
heterogeneity in the rate of treatment failure
with azithromycin (β = 0.826; p = 0.017; Figure 5).
There is no significant relationship between failure
rate difference and age (Figure 6); however,
the follow-up period had no significant effect
on heterogeneity in the rate of treatment
failure with azithromycin (p > 0.05; Figure 7).
There is no significant relationship between
failure rate difference and follow-up (p > 0.05;
Figure 8). In order to investigate the publication
bias, Begg’s test was used which showed
that there was no publication bias (z: 1.06;
p: 0.291).
Table III. Results of the univariate meta-regression analysis on the heterogeneity of the determinants of failure rate in azithromycin
users
Variables Coefficient Confidence Interval 95% P-value
Age (yr) 0.826 0.159 to 1.492 0.017
Publication year (yr) 0.107 -0.359 to 0.574 0.640
Follow-up (wk) -0.038 -2.211 to 2.135 0.971
Disease
Cervicitis 1 - -
Urethritis 7.422 -5.886 to 20.730 0.253
Genital chlamydia -0.030 -4.613 to 4.553 0.989
Design
Clinical trial 1 - -
RCT 5.464 -8.772 to 19.701 0.437
Sample size 0.003 -0.011 to 0.019 0.510
RCT: Randomized clinical trial
Table IV. Results of the univariate meta-regression analysis on the heterogeneity of the determinants of different proportion of
failure rate of azithromycin and other treatment strategies
Variables Coefficient Confidence interval 95% P-value
Age (yr) 0.029 -0.512 to 0.572 0.910
Publication year (yr) -0.025 -0.330 to 0.279 0.863
Follow-up (wk) 0.334 -0.822 to 1.490 0.554
Disease
Cervicitis 1 - -
Urethritis 1.641 -5.527 to 8.809 0.631
Genital chlamydia 0.871 -0.258 to 2.001 0.115
Sample size -0.002 -0.014 to 0.008 0.605
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Figure 2. A Pooled estimate of failure rate in azithromycin user based on a random effects model in total and in different design
study. The midpoint of each line segment shows the failure rate, the length of the line segment indicates the 95% confidence
interval in each study, and the diamond mark illustrates the pooled failure rate.
Figure 3. A Pooled estimate of failure rate in azithromycin user based on a random effects model in different diseases. The midpoint
of each line segment shows the failure rate, the length of the line segment indicates the 95% confidence interval in each study,
and the diamond mark illustrates the pooled failure rate in different design study.
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Figure 4. A Pooled estimate of failure rate difference (failure rate in intervention - failure rate in control) based on the random
effects model in total and in different diseases. The midpoint of each line segment shows the failure rate difference, the length of
the line segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled estimate.
Figure 5. Results of meta-regression on the relation between failure rate in azithromycin user and age. The size of the circles
represents the precision of each study. There is a significant relationship between failure rate and age. Failure rate relatively
increased with age.
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Figure 6. Results of meta-regression on the relation between
failure rate difference and age. The size of the circles
represents the precision of each study. There is no a significant
relationship between failure rate difference and age.
Figure 7. Results of meta-regression on the relation between
failure rate in azithromycin user and follow up. The size of the
circles represents the precision of each study. There is no a
significant relationship between failure rate and follow up.
Figure 8. Results of meta-regression on the relation between
failure rate difference and follow up. The size of the circles
represents the precision of each study. There is no a significant
relationship between failure rate difference and follow up.
4. Discussion
The present analysis offered a comprehensive
assessment of azithromycin failure in treating
patients infected with chlamydia. A number of
high-quality studies with a low risk of bias were
included in this assessment. Although the present
findings generally confirmed the effectiveness of
azithromycin in treating urogenital chlamydia, there
were controversial reports of azithromycin failure
rate differences.
According to the results of this meta-analysis,
the azithromycin failure rate in patients infected
with urogenital chlamydia was 11.23%. In one
study, Kissinger and colleagues showed that the
treatment failure with single 1 g dose of oral
azithromycin in men with urogenital chlamydia who
had sexual relations with women with chlamydial
cervicitis varied from 6.2% to 12.8%, which is
higher than the rate proposed by the WHO
(treatment failure rate < 5%) (43). In a systematic
review and meta-analysis, Kong and colleagues
showed that the random-effects pooled efficacy
for azithromycin (based on eight studies) was
82.9% and for doxycycline (based on five studies)
was 99.6%, resulting in a random-effects pooled
efficacy difference of 19.9% in favor of doxycycline.
The efficacy of single-dose azithromycin was
considerably lower than one week of doxycycline
for treating rectal chlamydia (44).
Schillinger and colleagues reported the
percentage of azithromycin treatment failure in
the group where only the women underwent
treatment versus the group where both women
and their sexual partners underwent treatment
as 15% and 12%, respectively, which means that
treating the sexual partner can help prevent the
recurrence of chlamydia infection (28). Kong and
colleagues compared the effectiveness of single
1 g dose of oral azithromycin with single 1 g r dose
of azithromycin plus twice daily 100 mg doses of
doxycycline over seven days in men with rectal
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chlamydia and reported failure rates of 12.8%
and 0% in the two groups, respectively (45). In
a meta-analysis conducted to determine and
compare the effectiveness of azithromycin and
doxycycline in treating genital chlamydia, Kong
and colleagues reported failure rates of 4% and
3% for azithromycin and doxycycline, respectively.
The subgroup analysis showed that the fixed and
random effects of the pooled efficacy difference in
symptomatic men were 4.7% and 5.5%, respectively
(46).
The present study revealed a failure rate
difference of 2.37%, which suggests that the rate
of treatment failure is higher with azithromycin than
with doxycycline and other examined medications
in treating chlamydia. In an in vitro study to
investigate the sensitivity of Chlamydiatrachomatis
strains, Ljubin and colleagues reported that all
the strains showed sensitivity to azithromycin
and doxycycline with a Minimum Inhibitory
Concentration (MIC) (47). Bhengraj and colleagues
used cell cultures to extract 21 clinical isolates
from women with symptoms of frequent chlamydia
infection and administered azithromycin and
doxycycline with MICs ≤ 0.125 and ≤ 0.25 µg/ml,
respectively. They reported that 38% of the
samples did not respond to the MIC, and a
reduction was observed in sensitivity to the current
first-line antibiotics (azithromycin and doxycycline)
for the treatment of chlamydia infections in
isolates taken from patients with recurring
infection (48).
Schwebke and colleagues investigated the
effects of single 1 g dose of azithromycin and twice
daily 100 mg doses of doxycycline over seven days
in patients with chlamydia urethritis, and also the
effect of adding 2 g of tinidazole to these treatment
regimens. They found that the addition of tinidazole
to the treatment regimen does not increase the rate
of recovery but eradicates chlamydia effectively.
The difference in clinical recovery between the
groups was not significant; however, doxycycline
had considerably better efficacy than azithromycin,
and the treatment failure was reported as 22.6% in
the azithromycin group and 5.2% in the doxycycline
group (27).
In the present study, the azithromycin failure
rate was 15.85% and the failure rate difference was
3.67% in patients with chlamydial urethritis. In their
three follow-ups of men with chlamydia urethritis
undergoing clinical examinations and urinary tract
culture, Lauharanta and colleagues reported the
failure rates in the first, second, and fifth weeks
of the follow-up as 4%, 10%, and 13% in the group
receiving single 1 g dose of azithromycin, and as 0%,
0%, and 7% in the group receiving twice daily 100 mg
doses of doxycycline over seven days, and no
significant differences were thus observed between
the two groups (39).
In a study conducted by Nilsen and colleagues,
treatment failure in the azithromycin and
doxycycline groups in the first and second weeks
of the follow-up were reported as 36.40% versus
32% and 11.5% versus 5.9%. These researchers
reported no significant differences in the treatment
failure rate between the two groups (41). In a clinical
trial on 606 men with chlamydia urethritis, Manhart
and colleagues compared the effects of a single
1 g dose of azithromycin and twice daily 100 mg
doses of doxycycline over seven days, and showed
a fairly poor clinical and microbiological recovery
rates in both groups, with no significant differences
observed between azithromycin and doxycycline,
as the treatment failure rates in the third and fifth
weeks of the follow-up were 17% and 36%, and 18%
and 39%, respectively (26).
Skerk and colleagues reported the treatment
failure rates of single 1 g dose of azithromycin,
once daily 500 mg dose of azithromycin over six
days, twice daily 100 mg doses of doxycycline
over seven days, and twice daily 100 mg doses
of doxycycline over 14 days as 5.2%, 0%, 5.2%,
and 0%, respectively (31). In a study conducted by
Takahashi and colleagues in Japan to determine
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the clinical effect of single 2 g dose of oral
azithromycin in men with chlamydia urethritis, the
treatment failure rate was 9.09% (25). In a study
by Whatley and colleagues, men diagnosed with
chlamydia urethritis were treated with single 1 g
dose of oral azithromycin, single 500 mg dose of
oral azithromycin on the first day and 250 mg oral
azithromycin on the 2nd and 3rd days, or twice
daily 100 mg doses of doxycycline over seven days.
The treatment failure rates with a single dose of
azithromycin and multiple doses of azithromycin
and doxycycline groups were reported as 23.5%,
5.20%, and 16.70%, respectively. All three regimens
were well tolerated by the patients, but the single
and multiple doses of azithromycin showed better
therapeutic effects than doxycycline (42).
In their study, Stamm and colleagues compared
the effects of single 1 g dose of oral azithromycin
and twice daily 100 mg doses of doxycycline
over seven days in men with chlamydial urethritis
and reported treatment failure rates of 19% for
azithromycin and 23% for doxycycline (37). Deguchi
and colleagues investigated the therapeutic effects
of a single 2 g dose of oral azithromycin and twice
daily 100 mg doses of sitafloxacin over seven days
in men with chlamydial urethritis. In their nine-week
follow-up, they showed treatment failure rates of 4%
in the azithromycin group and 0% in the sitafloxacin
group and recommended both azithromycin and
sitafloxacin as treatments for chlamydia infections
(49).
The present study showed a failure rate of
7.41% (CI 95%: 0.60%-14.22%) for azithromycin and a
failure rate difference of 0.86 (CI 95%: -1.14%-2.87%)
in patients with chlamydial cervicitis. Rustomjee
and colleagues compared the therapeutic effects
of single 1 g dose of azithromycin and twice daily
100 mg doses of doxycycline over seven days in
26 women with chlamydial cervicitis and showed
a similar failure rate of 0% in both groups (30).
In their study, Sendag and colleagues compared
the therapeutic effects of a single 1 g dose of
azithromycin and twice daily 100 mg doses of
doxycycline over seven days in women with
non-gonococcal mucopurulent endocervicitis. Two
weeks after the treatment, the infection eradication
rate was reported as 71.4% in the azithromycin
group and 77.3% in the doxycycline group, with
no statistically significant differences between the
single dose of azithromycin and oral doxycycline
(33).
Hillis and colleagues conducted a clinical trial in
women with cervicitis to determine the therapeutic
effects of single 1-g dose of azithromycin and twice
daily 100 mg doses of doxycycline over seven days
in preventing persistent or recurring chlamydia over
one month, and reported a treatment failure of
5.1% in the azithromycin group and 4.1% in the
doxycycline group (34). Brihmer and colleagues
compared women with chlamydial cervicitis in
terms of the therapeutic effects of a single 1 g r
oral dose of azithromycin and twice daily 300 mg
doses of lymecycline over seven days and reported
a treatment failure rate of 4.34% and 0% for
azithromycin and lymecycline, respectively (36).
Lowrence and colleagues investigated the recovery
rate with 1 g of azithromycin in six strains clinically
isolated through culture and PCR and reported no
genomic mutations in the ribosomal leukocytes that
could develop a direct resistance to azithromycin
(50).
In an in vivo study, Yeruva and colleagues
investigated the therapeutic effects of azithromycin
on the chlamydial infection of the gastrointestinal
tract and the cervix, and 10 eight-week-old rats were
administered a single oral dose of azithromycin 10
days after the infection at three different doses,
that is, 20, 40, and 80 mg/kg, or an intraperitoneal
injection of 10 mg/kg of doxycycline over seven
days. They reported that the antibiotic levels were
sufficient for the treatment of cervical infection
and all the rats receiving the three different
doses of azithromycin or doxycycline recovered
from the infections, but the treatment regimens
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were ineffective on gastrointestinal infections,
and further antibiotic assessments are needed
for chlamydial infections (51). Ossewaard and
colleagues compared the efficacy of single 1 g
dose of azithromycin with twice daily 100 mg
doses of doxycycline over the standard period of
seven days in treating cervical infections caused
by Chlamydiatrachomatis. The culture of all the
samples taken from both groups one and four
weeks after the initiation of treatment were negative
(52).
In the present study, the azithromycin failure rate
was 7.14% (CI 95%: 3.39%-10.9%) and the failure
rate difference was 1.90% (CI 95%: -0.04%-3.83%)
in patients with genital chlamydia. Thorpe and
colleagues compared the therapeutic effects of a
single 1 g oral dose of azithromycin and twice daily
100 mg doses of doxycycline over seven days in
women with urethritis or cervicitis and reported
treatment failure rates of 2% and 0%, respectively
(35). Geisler and colleagues studied men and
women with urogenital chlamydia who were
randomly assigned to a single-dose 1 g azithromycin
group or a twice daily 100 mg dose of doxycycline
group over seven days. Azithromycin was 97%
effective and doxycycline 100% (22). Beyda and
colleagues also investigated the effectiveness of
azithromycin in adolescent girls and boys with
cervicitis or urethritis caused by chlamydiatra
chomatis infection and reported the effectiveness
of azithromycin in treating chlamydia as 96.1% (24).
Hammerschlag and colleagues studied women
and men with clinical chlamydial cervicitis and
urethritis and reported treatment failures of 8.70%
and 14.80% for the single 1 g oral dose of
azithromycin and twice daily 100 mg doses of
doxycycline over seven days (38). Martin and
colleagues compared the therapeutic effects of
a single 1 g oral dose of azithromycin and twice
daily 100 mg doses of doxycycline over seven
days in women and men with chlamydial cervicitis
or urethritis and reported a treatment failure of
3.50% for azithromycin and 2.40% for doxycycline
(40). Geisler and colleagues reported the treatment
failure rates of 15.2% with a single 25 mg dose
of Rifalazil and 7.9% with a single 1 g dose of
azithromycin in women with genital chlamydia (23).
Jang and colleagues reported treatment failures
of azithromycin and doxycycline as 17.6% and
0%, respectively, in women with genital chlamydial
infections (29). Kacmar and colleagues conducted
a randomized clinical trial in patients with genital
chlamydia with a single 1 g dose of azithromycin
versus thrice daily 500 mg doses of amoxicillin over
seven days and reported the treatment failure rates
of azithromycin and amoxicillin as 5.26% and 20%,
respectively (32).
In one study, Quinn and colleagues stated that,
based on the recent recommendation of the Center
for Disease Control and Prevention (CDC) regarding
the high efficacy of azithromycin and doxycycline
(97% and 100%) in treating genital chlamydia, these
medications are valid and appropriate (53). In a
prospective cohort study to determine the recovery
rate of anorectal and cervicovaginal chlamydia
following treatment with a single 1 g oral dose of
azithromycin, Dukers and colleagues reported a
treatment failure of 15–27% over the three-week
and eight-week follow-ups after the initiation of the
treatment (54).
In another study, Tan and colleagues compared
the therapeutic effects of a single 1 g oral dose
of azithromycin and twice daily 100 mg doses
of doxycycline over seven days in treating men
with non-gonococcal urethritis and also female sex
workers with chlamydial cervicitis. Both medications
were highly successful in eradicating proven
chlamydial infections, and the treatment success
rate was 100% in men with NGU, and 96.6%
for azithromycin and 100% for doxycycline in
the cases of chlamydial cervicitis (55). In a
clinical trial conducted to assess the efficacy
of azithromycin, Steingrimsson and colleagues
stated that 96% of patients with genital chlamydia
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were cured with azithromycin (56). Importantly,
despite the reports of a high failure rate with 1 g
doses of azithromycin in the reviewed studies,
only two studies were found on the effect of
azithromycin on rectal chlamydia; however, they
did not satisfy our inclusion criteria. Given the
potential comorbidity of HIV and rectal chlamydial
infection, it is imperative that effective treatments
be available (Bernstein and colleagues). Given
these concerns, the current European guidelines
recommend that rectal chlamydial infection should
be treated with doxycycline over seven days (57).
Nonetheless, further clinical trials in this area
seem necessary.
As can be seen, the results of various studies on
the treatment failure of therapeutic regimens are
different in the treatment of urogenital chlamydia
trachomatis, which can be due to the difference
in the prevalence of the disease due to the
cultural and social conditions in different societies
as well as due to the differences in the type of
treatment and duration of treatment. According to
the WHO guidelines, those treatment regimens are
recommended for sexually transmitted infections
that present efficacy of more than 95% (58). Given
the present findings, policymakers should decide
whether a change is necessary for the guidelines
or not. Previous studies have shown that patients
with chlamydial infection symptoms have high
organism loads, which could be associated with
azithromycin treatment failure (59, 60). Given the
high failure rate of single-dose oral azithromycin
in treating chlamydial infections and the increasing
concerns about the serious complications caused
by the poor-to-moderate efficacy of azithromycin,
well-designed double-blind studies with high
statistical power are required on this subject.
4.1. Limitations of the study
Some studies that met the inclusion criteria
of the present study had been omitted from the
databases. Also, some of the recent studies on
azithromycin failure in treating chlamydia infections
were only accessible via their abstracts.
5. Conclusion
In the 21 reviewed clinical trials, the azithromycin
treatment failure rate was 11.23% and the failure rate
difference was 2.37%. Azithromycin has a higher
failure rate than doxycycline and other examined
medications in treating urogenital chlamydia
infections. Given that the treatment failure rate
with azithromycin is higher than that expected by
the WHO for the treatment of sexually transmitted
infections (under 5%), more well-designed studies
are needed to assess the therapeutic effects of
other medications on chlamydia infections.
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C, Ravel J, Delarocque-Astagneau E. The vaginal
microbiota andits association with Human Papillomavirus,
Chlamydia trachomatis, Neisseria gonorrhea and
Mycoplasma genitalium infections: a systematic review
and meta-analysis. Clin Microbiol Infect 2019; 25: 35–47.
[6] Giffard PM, Lilliebridge RA, Wilson J, Murray G, Phillips S,
Tabrizi SN, et al. Contaminated fingers: a potential cause
of Chlamydia trachomatis-positive urine specimens. Sex
Transm Infect 2018; 94: 32–36.
[7] Schuchardt L, Rupp J. Chlamydia trachomatis as the
cause of infectious infertility: acute, repetitive or persistent
long-term infection? Biology of Chelamydia 2016;
159–182.
[8] Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak
DB, et al. Risk of pelvic inflammatory disease in relation
to chlamydia and gonorrhea testing, repeat testing, and
positivity: a population-basedcohort study. Clin Infect Dis
2017; 66: 437–443.
[9] Olson KM, Tang J, Brown L, Press CG, Geisler WM.
HLA-DQB1* 06 is a risk marker for chlamydia reinfection
in African American women. Genes Immun 2019; 20:
69–73.
[10] Lohi KM, Kumar CA, Fonseca MN, Baveja SM, Panchal
SS. Study of Chlamydia trachomatis Infection in Infertile
Females at a Tertiary Care Hospital in Mumbai, India. Int J
Curr Microbiol App Sci 2018; 7: 1985–2000.
[11] WHO. WHO guidelines for the treatment of Chlamydia
trachomatis. Switzerland: World Health Organization;
2016.
[12] Unemo M, Salado-Rasmussen K, Hansen M, Olsen AO, Falk
M, Golparian D, et al. Clinical and analytical evaluation of
the new Aptima Mycoplasma genitalium assay, with data
on M. genitalium prevalence and antimicrobial resistance
in M. genitalium in Denmark, Norway and Sweden in 2016.
Clin Microbiol Infect 2018; 24: 533–539.
[13] Taylor BD, Zheng X, O’Connell CM, Wiesenfeld HC, Hillier
SL, Darville T. Risk factors for Mycoplasma genitalium
endometritis and incident infection: a secondary data
analysis of the T cell Response Against Chlamydia (TRAC)
Study. Sex Transm Infect 2018; 94: 414–420.
[14] Panos G. Prevalence studies of M. genitalium and other
sexually transmitted pathogens in high risk individuals
indicate the need for comprehensive investigation of STIs
for accurate diagnosis and effective treatment. Germs
2018; 8: 8–11.
[15] Couldwell DL, Lewis DA. Mycoplasma genitalium infection:
current treatment options, therapeutic failure, and
resistance-associated mutations. Infect Drug Resist 2015;
8: 147–161.
[16] Horner P, Ingle SM, Garrett F, Blee K, Kong F, Muir P, et al.
Which azithromycin regimen should be used for treating
Mycoplasma genitalium? A meta-analysis. Sex Transm
Infect 2018; 94: 14–20.
[17] Bradshaw CS, Horner PJ, Jensen JS White PJ. Syndromic
management of STIs and the threat of untreatable
Mycoplasma genitalium. Lancet Infect Dis 2018; 18:
251–252.
[18] Rothman A, Jean R. Macrolide-Resistant Mycoplasma:
An Increasing Problem. In: B52. Bacterial Infection Case
Reports: American Thoracic Society; 2018: A3593.
[19] Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of
macrolide-resistant Mycoplasma pneumoniae pneumonia
in children. Expert Rev Anti Infect Ther 2018; 16: 23–34.
[20] Abdi F, Mobedi H, Bayat F, Mosaffa N, Dolatian M,
Ramezani Tehrani F. The effects of transdermal estrogen
delivery on bone mineral density in postmenopausal
women: a meta-analysis. Iran J Pharm Res 2017; 16:
380–389.
[21] Abdi F, Alimoradi Z, Haqi P, Mahdizad F. Effects of
phytoestrogens on bone mineral density during the
menopause transition: a systematic review of randomized,
controlled trials. Climacteric 2016; 19: 535–545.
[22] Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry
RC, et al. Azithromycin versus doxycycline for urogenital
Chlamydia trachomatis infection. N Engl J Med 2015; 373:
2512–2521.
[23] Geisler WM, Pascual MLG, Mathew J, Koltun WD, Morgan F,
Batteiger BE, et al. Randomized, double-blind, multi-center
safety and efficacy study of rifalazil compared with
azithromycin for the treatment of uncomplicated genital
Chlamydia trachomatis infection in women. Antimicrobial
Agents and Chemotherapy 2014; 58: 4014–4019.
[24] Beyda RM, Benjamins LJ, Symanski E, Swartz M, Risser
WL, Eissa M. Azithromycin efficacy in the treatment
of Chlamydia trachomatis among detained youth. Sex
Transm Dis 2014; 41: 592–594.
[25] Takahashi S, Kiyota H, Ito S, Iwasawa A, Hiyama Y, Uehara
T, et al. Clinical efficacy of a single two gram dose
of azithromycin extended release for male patients with
urethritis. Antibiotics 2014; 3: 109–120.
[26] Manhart LE, Gillespie CW, Lowens MS, Khosropour CM,
Colombara DV, Golden MR. et al. Standard treatment
regimens for nongonococcal urethritis have similar but
declining cure rates: a randomized controlled trial. Clin
Infect Dis 2013; 56: 934–942.
[27] Schwebke JR, Rompalo A, Taylor S, Sena AC, Martin
DH, Lopez LM, et al. Re-evaluating the treatment
of nongonococcal urethritis: emphasizing emerging
pathogens-a randomized clinical trial. Clin Infect Dis 2011;
52: 163–170.
[28] Schillinger JA, Kissinger P, Calvet H, Whittington WL,
Ransom RL, Sternberg MR, et al. Patient-delivered
partner treatment with azithromycin to prevent repeated
Chlamydia trachomatis infection among women: a
randomized, controlled trial. Sex Transm Dis 2003; 30:
49–56.
[29] Jang D, Sellors J, Howard M, Mahony J, Frost E, Patrick
D, et al. Correlation between culture testing of swabs
and ligase chain reaction of first void urine from patients
recently treated for Chlamydia trachomatis. Sex Transm
Infect 2003; 79: 237–239.
[30] Rustomjee R, Kharsany AB, Connolly CA, Karim SS.
A randomized controlled trial of azithromycin versus
doxycycline/ciprofloxacin for the syndromic management
of sexually transmitted infections in a resource-poor
setting. J Antimicrob Chemother 2002; 49: 875–878.
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